Brain

Unlocking the Secrets to a Sharper Mind and Healthier Cells

Retrieved on: 
Wednesday, April 17, 2024
Brain, Oxidative stress, Dementia, CDC, Motivation, Cell, Research, History, Nutrient, Cell membrane, Ageing

“Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.

Key Points: 
  • “Our bodies and brains are under constant barrage from environmental toxins and lifestyle choices that significantly harm our cellular health,” explains Return Healthy’s CEO, Dr. Werner Vosloo, ND.
  • These products replenish essential nutrients, enhance cellular repair mechanisms, and protect against oxidative stress.
  • They are pivotal for maintaining cell membrane integrity, which is essential for the brain cells that manage information processing and cognitive performance.
  • Return Healthy’s Cell Stabilization Plan is a testament to the company’s commitment to empower individuals to take control of their healthspan with preventive self-care and advanced nutritional support.

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

Retrieved on: 
Wednesday, April 17, 2024
USD, Brain, University, Cancer, Genomics, Mutation, GTG, Methylation, Health, Survival, Breast, DNA methylation, ASX, DNA, Patient, GVR, Lung, Disease, Melanoma, Neoplasm, Liquid biopsy, Medical imaging

Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.

Key Points: 
  • Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.
  • Earlier detection of a range of cancers leads to significantly improved patient outcomes.
  • This will significantly drive uptake by making genomic tests widely available and financially accessible to eligible patients.
  • This portfolio of new genomic tests will dramatically change the landscape of oncology diagnostics and help achieve better treatment outcomes for patients.

Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale

Retrieved on: 
Wednesday, April 17, 2024
Brain, Stroke, Neurological disorder, Health, Population health, Partnership, Dementia, Patient, Caregiver, DSM-IV codes, Constant, Pharmaceutical industry

Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.

Key Points: 
  • Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.
  • With the partnership, Elara clinicians can now deliver a highly-personalized course of therapeutic exercises – and measure patient progress – to best meet the needs of patients recovering from conditions such as stroke, brain injury or dementia.
  • Simultaneously, Elara patients are given unlimited access to the Constant Therapy mobile app – allowing them to maintain engagement with their therapy program outside of their scheduled clinical visits.
  • “Elara Caring is well recognized for its use of advanced technology and data insights that help proactively treat and monitor patients,” said Mark Salley, VP of Innovations and Rehab Solutions, Elara Caring.

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Retrieved on: 
Tuesday, April 16, 2024
GRN, Brain, FTD, United, Hospital, Dementia, Frontotemporal dementia, Spine, Thalamus, Patient, Clinical trial, Medical device

SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.

Key Points: 
  • SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.
  • “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families.
  • The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • “We are proud to support AviadoBio and the team at Mazowiecki Szpital Bródnowski Hospital, as well as other clinical trial sites to come in Europe and the United States.”
    More information about the ASPIRE-FTD study can be found at https://clinicaltrials.gov/study/NCT06064890.

UsAgainstAlzheimer’s Launches 2024 Brain Health Academy

Retrieved on: 
Tuesday, April 16, 2024
Brain, Nutrition, Risk, Dietitian, Eisai, Doctor, Dementia, Growth, Tivity Health, Ageing, Patient, Society, AARP, American Heart Association

Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.

Key Points: 
  • Each of the hour-long virtual sessions will be recorded and available for on-demand viewing up to 60 days after the live presentation.
  • A testament to the Academy’s impact, more than 5,300 individuals benefitted from the free, evidence-based education program.
  • More than half of participants reported a significant shift in their approach to brain health and how they discuss risk factors and dementia with their patients.
  • “With educational programs like the Brain Health Academy, we can empower health care professionals to better serve those whom they serve by counseling them about the importance of promoting and protecting their brain health and reducing their risk of developing brain disease.”
    The Brain Health Academy is made possible through its collaborative efforts with partners, including the Academy of Doctors of Audiology, Academy of Nutrition and Dietetics, American Society on Aging, AARP, American Academy of Sleep Medicine, American Heart Association, American College of Lifestyle Medicine, Centers for Disease Control and Prevention, Eisai, Humana, Physical Activity Alliance, Tivity Health, and USAging.

Study: This Brain Training is Effective for Just About Everyone

Retrieved on: 
Tuesday, April 16, 2024
Education, Brain, Huber loss, Risk, NIH, Hearing loss, Cognition, Research, Grammatical mood, Attention, Exercise, Incidence, Medicare, Athlete, Memory, Quality of life, SAN, Nursing

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- A large, long-term study of different types of brain training found only the training in the brain health app BrainHQ , made by Posit Science , was effective without regard to a study participant’s demographic or health characteristics.

Key Points: 
  • SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- A large, long-term study of different types of brain training found only the training in the brain health app BrainHQ , made by Posit Science , was effective without regard to a study participant’s demographic or health characteristics.
  • The report, published in the journal of Alzheimer’s and Dementia , examined data from 2,788 participants in the NIH-funded, 20-year, Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Study.
  • The memory training had higher effect among participants with higher education, better self-rated health, and hearing difficulty.
  • The reasoning training had higher effect in people with higher baseline cognition without vision difficulties.

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Tuesday, April 16, 2024
Science, APOE, American Academy, Brain, ABOS, Safety, Hope, Neurogranin, Poster, Plasma, Colorado Convention Center, ES2, GFAP, Patient, Incidence, AAN, CSF, Biomarker, Annual general meeting, Plaque, Cerebrospinal fluid

Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early AD.

Key Points: 
  • Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early AD.
  • Acumen remains on track to initiate the ALTITUDE-AD placebo-controlled Phase 2 trial of sabirnetug in the first half of 2024.
  • Based on safety, target engagement and biomarker data from the INTERCEPT-AD trial, Acumen has determined sabirnetug doses of 35 mg/kg Q4W and 50 mg/kg Q4W in ALTITUDE-AD.
  • Acumen also plans to initiate a Phase 1 bioavailability study to support a subcutaneous dosing option of sabirnetug in mid-2024, as announced in November 2023 .

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
Monday, April 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

Novocure Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, METIS, Congress, Cancer, Paclitaxel, EDT, Investment, Temozolomide, Food, Survival, Gynaecology, Immunotherapy, Lung cancer, Partnership, GBM, Webcast, Glioblastoma, Disclosure, IND, Prescription, ASCO, Regulation Fair Disclosure, Patient, Brain, Society, Loss, Regulation, PLD, Marketing, Clinical trial, NSCLC, PMA, Investigational New Drug, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.
  • Research, development, and clinical studies expenses for the quarter were $51.6 million, a decrease of 14% from the same period in 2023.
  • Sales and marketing expenses for the quarter were $55.2 million, an increase of 8% compared to the same period in 2023.
  • Novocure will host a conference call and webcast to discuss first quarter 2024 financial results at 8:00 a.m. EDT today, Thursday, May 2, 2024.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.